BioXcel Therapeutics (BTAI) Other Operating Expenses (2022 - 2026)

BioXcel Therapeutics' Other Operating Expenses history runs 5 years deep, the most recent figure standing at $283000.0 for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 1921.43% year-over-year to $283000.0 in Q1 2026; TTM through Mar 2026 was $433000.0, a 79.15% decrease from a year earlier, with the FY2025 full-year figure at $164000.0, down 92.35% from the prior year.
• Other Operating Expenses grew to $283000.0 in Q1 2026 per BTAI's latest filing, from $32000.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $1.2 million in Q3 2024 and bottomed at $9000.0 in Q4 2022.
• The 5-year median for Other Operating Expenses is $62000.0 (2024), against an average of $258066.7.
• Across the five-year window, Other Operating Expenses soared 7833.33% in 2023 and plunged 99.06% in 2025, its largest moves.
• Year by year, Other Operating Expenses stood at $9000.0 in 2022, then surged by 7833.33% to $714000.0 in 2023, then climbed by 16.39% to $831000.0 in 2024, then plunged by 96.15% to $32000.0 in 2025, then jumped by 784.38% to $283000.0 in 2026.
• Per Business Quant, the three latest BTAI Other Operating Expenses figures stand at $283000.0 (Q1 2026), $32000.0 (Q4 2025), and $11000.0 (Q3 2025).